Pharmaceutical giant Eli Lilly reports profit of $17.6 billion. This was above analysts' expectations of profit of $16 billion, according to a Bloomberg report.
The result was driven primarily by increased volumes for the company's weight-loss products. Revenue for the weight-loss drugs Zepbound and Mounjaro came in at $3.59 billion and $6.52 billion, respectively. This was clearly above analysts' expectations.
The company raises its forecast for the full year 2025.
